Low serum docosahexaenoic acid is associated with progression of coronary atherosclerosis in statin-treated patients with diabetes mellitus: Results of the treatment with statin on atheroma regression evaluated by intravascular ultrasound with virtual histology (TRUTH) study

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Nozue, Tsuyoshi ^a   Yamamoto, Shingo ^b   Tohyama, Shinichi ^c   Fukui, Kazuki ^d   Umezawa, Shigeo ^e   Onishi, Yuko ^e   Kunishima, Tomoyuki ^f   Sato, Akira ^g   Nozato, Toshihiro ^h   Miyake, Shogo ⁱ   Takeyama, Youichi ^j   Morino, Yoshihiro ^k   Yamauchi, Takao ^l   Muramatsu, Toshiya ^m   Hibi, Kiyoshi ⁿ   Terashima, Mitsuyasu ^o   Michishita, Ichiro ^a  

^a YOKOHAMA SAKAE KYOSAI HOSPITAL   (Japan)

^b Tsurumi Nishiguchi Hospital   (Japan)

^c Yokohama Seamen's Insurance Hospital   (Japan)

^d Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

^e Hiratsuka Kyosai Hospital   (Japan)

^f TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g YOKOSUKA KYOSAI HOSPITAL   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION   (Japan)

ⁱ Ebina General Hospital   (Japan)

^j Showa University Fujigaoka Rehabilitation Hospital   (Japan)

^k TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^m SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

ⁿ YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^o Cardiovascular Imaging Center   (Japan)

more..

Author keywords

Atheroma; Coronary atherosclerosis; Diabetes mellitus; Statin; Virtual histology intravascular ultrasound

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; PITAVASTATIN; PRAVASTATIN; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROMA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HISTOLOGY; HUMAN; HYPERTENSION; INSULIN TREATMENT; INTRAVASCULAR ULTRASOUND; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; VIRTUAL HISTOLOGY;

AGED; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE PROGRESSION; DOCOSAHEXAENOIC ACIDS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL; VIRTUAL REALITY EXPOSURE THERAPY;

EID: 84892418595     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-13     Document Type: Article

References (40)

1. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004, 164:1422-1426. 10.1001/archinte.164.13.1422, 15249351.
2. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, JAPAN-ACS Investigators Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009, 54:293-302. 10.1016/j.jacc.2009.04.033, 19608026, JAPAN-ACS Investigators.
3. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504. 10.1056/NEJMoa040583, 15007110, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.
4. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435. 10.1056/NEJMoa050461, 15755765, Wenger NK; Treating to New Targets (TNT) Investigators.
5. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, O'Brien E, Ostergren J, ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-Scandinavian cardiac outcomes trial--lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158. 10.1016/S0140-6736(03)12948-0, 12686036, ASCOT investigators.
6. Oikawa S, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Saito Y, Sasaki J, Shimamoto K, Itakura H, J-LIT Study Group Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). Atherosclerosis 2007, 191:440-446. 10.1016/j.atherosclerosis.2006.04.017, 16765358, J-LIT Study Group.
7. Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Michishita I, TRUTH Investigators Impact of diabetes mellitus on coronary atherosclerosis and plaque composition under statin therapy - subanalysis of the TRUTH study. Circ J 2012, 76:2188-2196. 10.1253/circj.CJ-11-1303, 22785608, TRUTH Investigators.
8. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008, 52:255-262. 10.1016/j.jacc.2008.03.051, 18634979.
9. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, JAPAN-ACS Investigators Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome-serial intravascular ultrasound observations from the Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome trial (the JAPAN-ACS Trial). Circ J 2010, 74:1165-1174. 10.1253/circj.CJ-09-0766, 20467151, JAPAN-ACS Investigators.
10. Nozue T, Yamamoto S, Tohyama S, Umezawa S, Kunishima T, Sato A, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Sozu T, Michishita I. Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. Am Heart J 2012, 163:191-199. 10.1016/j.ahj.2011.11.004, 22305836.
11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
12. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 2001, 37:1478-1492. 10.1016/S0735-1097(01)01175-5, 11300468.
13. Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, JELIS Investigators Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA lipid intervention study (JELIS). Atherosclerosis 2009, 206:535-539. 10.1016/j.atherosclerosis.2009.03.029, 19447387, JELIS Investigators.
14. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002, 346:1113-1118. 10.1056/NEJMoa012918, 11948270.
15. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the cardiovascular health study. Am J Clin Nutr 2003, 77:319-325.
16. Domei T, Yokoi H, Kuramitsu S, Soga Y, Arita T, Ando K, Shirai S, Kondo K, Sakai K, Goya M, Iwabuchi M, Ueeda M, Nobuyoshi M. Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J 2012, 76:423-429. 10.1253/circj.CJ-11-0941, 22156311.
17. Ninomiya T, Nagata M, Hata J, Hirakawa Y, Ozawa M, Yoshida D, Ohara T, Kishimoto H, Mukai N, Fukuhara M, Kitazono T, Kiyohara Y. Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama study. Atherosclerosis 2013, 231:261-267. 10.1016/j.atherosclerosis.2013.09.023, 24267237.
18. de Oliveira Otto MC, Wu JH, Baylin A, Vaidya D, Rich SS, Tsai MY, Jacobs DR, Mozaffarian D. Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2013, 2:e000506. 10.1161/JAHA.113.000506, 3886748, 24351702.
19. Hou L, Lian K, Yao M, Shi Y, Lu X, Fang L, He T, Jiang L. Reduction of n-3 PUFAs, specifically DHA and EPA, and enhancement of peroxisomal beta-oxidation in type 2 diabetic rat heart. Cardiovasc Diabetol 2012, 11:126. 10.1186/1475-2840-11-126, 3490815, 23057715.
20. Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S, JPHC Study Group Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) study cohort I. Circulation 2006, 113:195-202. 10.1161/CIRCULATIONAHA.105.581355, 16401768, JPHC Study Group.
21. Mozaffarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS. Cardiovascular Health Study. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the cardiovascular health study. Circulation 2003, 107:1372-1377. 10.1161/01.CIR.0000055315.79177.16, 12642356.
22. Oliveira Junior SA, Padovani CR, Rodrigues SA, Silva NR, Martinez PF, Campos DH, Okoshi MP, Okoshi K, Dal-Pai M, Cicogna AC. Extensive impact of saturated fatty acids on metabolic and cardiovascular profile in rats with diet-induced obesity: a canonical analysis. Cardiovasc Diabetol 2013, 12:65. 10.1186/1475-2840-12-65, 3679825, 23587409.
23. Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol 2013, 12:100. 10.1186/1475-2840-12-100, 3718763, 23835245.
24. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 58:2047-2067. 10.1016/j.jacc.2011.06.063, 22051327.
25. Ratnayake WM, Galli C. Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Ann Nutr Metab 2009, 55:8-43. 10.1159/000228994, 19752534.
26. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098. 10.1016/S0140-6736(07)60527-3, 17398308, Japan EPA lipid intervention study (JELIS) Investigators.
27. GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455. GISSI-Prevenzione Investigators.
28. Erkkilä AT, Matthan NR, Herrington DM, Lichtenstein AH. Higher plasma docosahexaenoic acid is associated with reduced progression of coronary atherosclerosis in women with CAD. J Lipid Res 2006, 47:2814-2819. 10.1194/jlr.P600005-JLR200, 16983146.
29. Sala-Vila A, Cofán M, Pérez-Heras A, Núñez I, Gilabert R, Junyent M, Mateo-Gallego R, Cenarro A, Civeira F, Ros E. Fatty acids in serum phospholipids and carotid intima-media thickness in Spanish subjects with primary dyslipidemia. Am J Clin Nutr 2010, 92:186-193. 10.3945/ajcn.2009.28807, 20463042.
30. Sekikawa A, Kadowaki T, El-Saed A, Okamura T, Sutton-Tyrrell K, Nakamura Y, Evans RW, Mitsunami K, Edmundowicz D, Nishio Y, Nakata K, Kadota A, Otake T, Miura K, Choo J, Abbott RD, Kuller LH, Curb JD, Ueshima H, ERA JUMP Study group Differential association of docosahexaenoic and eicosapentaenoic acids with carotid intima-media thickness. Stroke 2011, 42:2538-2543. 10.1161/STROKEAHA.110.613042, 3164236, 21757663, ERA JUMP Study group.
31. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
32. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289. 10.1016/S0140-6736(05)67528-9, 16214598.
33. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM, PERISCOPE Investigators Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299:1561-1573. 10.1001/jama.299.13.1561, 18378631, PERISCOPE Investigators.
34. Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, Sawada T, Kawamori H, Kato H, Miyoshi N, Hirata K. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J 2009, 73:343-351. 10.1253/circj.CJ-08-0699, 19096190.
35. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006, 29:1220-1226. 10.2337/dc05-2465, 16731999.
36. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004, 110:227-239. 10.1161/01.CIR.0000133317.49796.0E, 15249516, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.
37. Sakamoto T, Ogawa H. " Just make it lower" is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: LDL-cholesterol: the lower, the better; is it true for Asians? (Con). Circ J 2010, 74:1731-1741. 10.1253/circj.CJ-10-0537, 20671372.
38. Arai H, Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, JAPAN-ACS Investigators More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome-sub-analysis of JAPAN-ACS study. J Atheroscler Thromb 2010, 17:1096-1107. 10.5551/jat.5660, 20675955, JAPAN-ACS Investigators.
39. Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Michishita I. Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention. Am J Cardiol 2013, 111:1570-1575. 10.1016/j.amjcard.2013.01.327, 23497779.
40. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316. 10.1001/jama.292.11.1307, 15337732, Investigators.